Global Hemophilia Drugs Market Research Report 2023

Global Hemophilia Drugs Market Research Report 2023

Table of Contents
1 Hemophilia Drugs Market Overview
1.1 Product Overview and Scope of Hemophilia Drugs
1.2 Hemophilia Drugs Segment by Type
1.2.1 Global Hemophilia Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Hemophilia A
1.2.3 Inhibitors
1.2.4 Hemophilia B
1.2.5 Von Willebrand Disease
1.3 Hemophilia Drugs Segment by Application
1.3.1 Global Hemophilia Drugs Market Value by Application: (2023-2029)
1.3.2 Recombinant Therapies
1.3.3 Plasma-Derived Therapies
1.4 Global Hemophilia Drugs Market Size Estimates and Forecasts
1.4.1 Global Hemophilia Drugs Revenue 2018-2029
1.4.2 Global Hemophilia Drugs Sales 2018-2029
1.4.3 Global Hemophilia Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Hemophilia Drugs Market Competition by Manufacturers
2.1 Global Hemophilia Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Hemophilia Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Hemophilia Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Hemophilia Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Hemophilia Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hemophilia Drugs, Product Type & Application
2.7 Hemophilia Drugs Market Competitive Situation and Trends
2.7.1 Hemophilia Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hemophilia Drugs Players Market Share by Revenue
2.7.3 Global Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hemophilia Drugs Retrospective Market Scenario by Region
3.1 Global Hemophilia Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Hemophilia Drugs Global Hemophilia Drugs Sales by Region: 2018-2029
3.2.1 Global Hemophilia Drugs Sales by Region: 2018-2023
3.2.2 Global Hemophilia Drugs Sales by Region: 2024-2029
3.3 Global Hemophilia Drugs Global Hemophilia Drugs Revenue by Region: 2018-2029
3.3.1 Global Hemophilia Drugs Revenue by Region: 2018-2023
3.3.2 Global Hemophilia Drugs Revenue by Region: 2024-2029
3.4 North America Hemophilia Drugs Market Facts & Figures by Country
3.4.1 North America Hemophilia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Hemophilia Drugs Sales by Country (2018-2029)
3.4.3 North America Hemophilia Drugs Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hemophilia Drugs Market Facts & Figures by Country
3.5.1 Europe Hemophilia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Hemophilia Drugs Sales by Country (2018-2029)
3.5.3 Europe Hemophilia Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hemophilia Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Hemophilia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Hemophilia Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Hemophilia Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hemophilia Drugs Market Facts & Figures by Country
3.7.1 Latin America Hemophilia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Hemophilia Drugs Sales by Country (2018-2029)
3.7.3 Latin America Hemophilia Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hemophilia Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Hemophilia Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Hemophilia Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Hemophilia Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hemophilia Drugs Sales by Type (2018-2029)
4.1.1 Global Hemophilia Drugs Sales by Type (2018-2023)
4.1.2 Global Hemophilia Drugs Sales by Type (2024-2029)
4.1.3 Global Hemophilia Drugs Sales Market Share by Type (2018-2029)
4.2 Global Hemophilia Drugs Revenue by Type (2018-2029)
4.2.1 Global Hemophilia Drugs Revenue by Type (2018-2023)
4.2.2 Global Hemophilia Drugs Revenue by Type (2024-2029)
4.2.3 Global Hemophilia Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Hemophilia Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Hemophilia Drugs Sales by Application (2018-2029)
5.1.1 Global Hemophilia Drugs Sales by Application (2018-2023)
5.1.2 Global Hemophilia Drugs Sales by Application (2024-2029)
5.1.3 Global Hemophilia Drugs Sales Market Share by Application (2018-2029)
5.2 Global Hemophilia Drugs Revenue by Application (2018-2029)
5.2.1 Global Hemophilia Drugs Revenue by Application (2018-2023)
5.2.2 Global Hemophilia Drugs Revenue by Application (2024-2029)
5.2.3 Global Hemophilia Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Hemophilia Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Baxalta
6.1.1 Baxalta Corporation Information
6.1.2 Baxalta Description and Business Overview
6.1.3 Baxalta Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Baxalta Hemophilia Drugs Product Portfolio
6.1.5 Baxalta Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bayer Hemophilia Drugs Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 CSL Behring
6.3.1 CSL Behring Corporation Information
6.3.2 CSL Behring Description and Business Overview
6.3.3 CSL Behring Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 CSL Behring Hemophilia Drugs Product Portfolio
6.3.5 CSL Behring Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Hemophilia Drugs Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Alnylam Pharmaceuticals
6.5.1 Alnylam Pharmaceuticals Corporation Information
6.5.2 Alnylam Pharmaceuticals Description and Business Overview
6.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolio
6.5.5 Alnylam Pharmaceuticals Recent Developments/Updates
6.6 BioMarin
6.6.1 BioMarin Corporation Information
6.6.2 BioMarin Description and Business Overview
6.6.3 BioMarin Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 BioMarin Hemophilia Drugs Product Portfolio
6.6.5 BioMarin Recent Developments/Updates
6.7 Catalyst Biosciences
6.6.1 Catalyst Biosciences Corporation Information
6.6.2 Catalyst Biosciences Description and Business Overview
6.6.3 Catalyst Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Catalyst Biosciences Hemophilia Drugs Product Portfolio
6.7.5 Catalyst Biosciences Recent Developments/Updates
6.8 Dimension Therapeutics
6.8.1 Dimension Therapeutics Corporation Information
6.8.2 Dimension Therapeutics Description and Business Overview
6.8.3 Dimension Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Dimension Therapeutics Hemophilia Drugs Product Portfolio
6.8.5 Dimension Therapeutics Recent Developments/Updates
6.9 F. Hoffmann-La Roche
6.9.1 F. Hoffmann-La Roche Corporation Information
6.9.2 F. Hoffmann-La Roche Description and Business Overview
6.9.3 F. Hoffmann-La Roche Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 F. Hoffmann-La Roche Hemophilia Drugs Product Portfolio
6.9.5 F. Hoffmann-La Roche Recent Developments/Updates
6.10 Grifols
6.10.1 Grifols Corporation Information
6.10.2 Grifols Description and Business Overview
6.10.3 Grifols Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Grifols Hemophilia Drugs Product Portfolio
6.10.5 Grifols Recent Developments/Updates
6.11 Octapharma
6.11.1 Octapharma Corporation Information
6.11.2 Octapharma Hemophilia Drugs Description and Business Overview
6.11.3 Octapharma Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Octapharma Hemophilia Drugs Product Portfolio
6.11.5 Octapharma Recent Developments/Updates
6.12 Sangamo Biosciences
6.12.1 Sangamo Biosciences Corporation Information
6.12.2 Sangamo Biosciences Hemophilia Drugs Description and Business Overview
6.12.3 Sangamo Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Sangamo Biosciences Hemophilia Drugs Product Portfolio
6.12.5 Sangamo Biosciences Recent Developments/Updates
6.13 Spark Therapeutics
6.13.1 Spark Therapeutics Corporation Information
6.13.2 Spark Therapeutics Hemophilia Drugs Description and Business Overview
6.13.3 Spark Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Spark Therapeutics Hemophilia Drugs Product Portfolio
6.13.5 Spark Therapeutics Recent Developments/Updates
6.14 Swedish Orphan Biovitrum
6.14.1 Swedish Orphan Biovitrum Corporation Information
6.14.2 Swedish Orphan Biovitrum Hemophilia Drugs Description and Business Overview
6.14.3 Swedish Orphan Biovitrum Hemophilia Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolio
6.14.5 Swedish Orphan Biovitrum Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hemophilia Drugs Industry Chain Analysis
7.2 Hemophilia Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hemophilia Drugs Production Mode & Process
7.4 Hemophilia Drugs Sales and Marketing
7.4.1 Hemophilia Drugs Sales Channels
7.4.2 Hemophilia Drugs Distributors
7.5 Hemophilia Drugs Customers
8 Hemophilia Drugs Market Dynamics
8.1 Hemophilia Drugs Industry Trends
8.2 Hemophilia Drugs Market Drivers
8.3 Hemophilia Drugs Market Challenges
8.4 Hemophilia Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Hemophilia Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Hemophilia Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Hemophilia Drugs Market Competitive Situation by Manufacturers in 2022
Table 4. Global Hemophilia Drugs Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Hemophilia Drugs Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Hemophilia Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Hemophilia Drugs Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Hemophilia Drugs Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Hemophilia Drugs, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Hemophilia Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Hemophilia Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Hemophilia Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Hemophilia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemophilia Drugs as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Hemophilia Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Hemophilia Drugs Sales by Region (2018-2023) & (K Units)
Table 18. Global Hemophilia Drugs Sales Market Share by Region (2018-2023)
Table 19. Global Hemophilia Drugs Sales by Region (2024-2029) & (K Units)
Table 20. Global Hemophilia Drugs Sales Market Share by Region (2024-2029)
Table 21. Global Hemophilia Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Hemophilia Drugs Revenue Market Share by Region (2018-2023)
Table 23. Global Hemophilia Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Hemophilia Drugs Revenue Market Share by Region (2024-2029)
Table 25. North America Hemophilia Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Hemophilia Drugs Sales by Country (2018-2023) & (K Units)
Table 27. North America Hemophilia Drugs Sales by Country (2024-2029) & (K Units)
Table 28. North America Hemophilia Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Hemophilia Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Hemophilia Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Hemophilia Drugs Sales by Country (2018-2023) & (K Units)
Table 32. Europe Hemophilia Drugs Sales by Country (2024-2029) & (K Units)
Table 33. Europe Hemophilia Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Hemophilia Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Hemophilia Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Hemophilia Drugs Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Hemophilia Drugs Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Hemophilia Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Hemophilia Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Hemophilia Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Hemophilia Drugs Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Hemophilia Drugs Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Hemophilia Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Hemophilia Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Hemophilia Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Hemophilia Drugs Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Hemophilia Drugs Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Hemophilia Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Hemophilia Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Hemophilia Drugs Sales (K Units) by Type (2018-2023)
Table 51. Global Hemophilia Drugs Sales (K Units) by Type (2024-2029)
Table 52. Global Hemophilia Drugs Sales Market Share by Type (2018-2023)
Table 53. Global Hemophilia Drugs Sales Market Share by Type (2024-2029)
Table 54. Global Hemophilia Drugs Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Hemophilia Drugs Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Hemophilia Drugs Revenue Market Share by Type (2018-2023)
Table 57. Global Hemophilia Drugs Revenue Market Share by Type (2024-2029)
Table 58. Global Hemophilia Drugs Price (USD/Unit) by Type (2018-2023)
Table 59. Global Hemophilia Drugs Price (USD/Unit) by Type (2024-2029)
Table 60. Global Hemophilia Drugs Sales (K Units) by Application (2018-2023)
Table 61. Global Hemophilia Drugs Sales (K Units) by Application (2024-2029)
Table 62. Global Hemophilia Drugs Sales Market Share by Application (2018-2023)
Table 63. Global Hemophilia Drugs Sales Market Share by Application (2024-2029)
Table 64. Global Hemophilia Drugs Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Hemophilia Drugs Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Hemophilia Drugs Revenue Market Share by Application (2018-2023)
Table 67. Global Hemophilia Drugs Revenue Market Share by Application (2024-2029)
Table 68. Global Hemophilia Drugs Price (USD/Unit) by Application (2018-2023)
Table 69. Global Hemophilia Drugs Price (USD/Unit) by Application (2024-2029)
Table 70. Baxalta Corporation Information
Table 71. Baxalta Description and Business Overview
Table 72. Baxalta Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Baxalta Hemophilia Drugs Product
Table 74. Baxalta Recent Developments/Updates
Table 75. Bayer Corporation Information
Table 76. Bayer Description and Business Overview
Table 77. Bayer Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 78. Bayer Hemophilia Drugs Product
Table 79. Bayer Recent Developments/Updates
Table 80. CSL Behring Corporation Information
Table 81. CSL Behring Description and Business Overview
Table 82. CSL Behring Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 83. CSL Behring Hemophilia Drugs Product
Table 84. CSL Behring Recent Developments/Updates
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 88. Pfizer Hemophilia Drugs Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Alnylam Pharmaceuticals Corporation Information
Table 91. Alnylam Pharmaceuticals Description and Business Overview
Table 92. Alnylam Pharmaceuticals Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 93. Alnylam Pharmaceuticals Hemophilia Drugs Product
Table 94. Alnylam Pharmaceuticals Recent Developments/Updates
Table 95. BioMarin Corporation Information
Table 96. BioMarin Description and Business Overview
Table 97. BioMarin Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 98. BioMarin Hemophilia Drugs Product
Table 99. BioMarin Recent Developments/Updates
Table 100. Catalyst Biosciences Corporation Information
Table 101. Catalyst Biosciences Description and Business Overview
Table 102. Catalyst Biosciences Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 103. Catalyst Biosciences Hemophilia Drugs Product
Table 104. Catalyst Biosciences Recent Developments/Updates
Table 105. Dimension Therapeutics Corporation Information
Table 106. Dimension Therapeutics Description and Business Overview
Table 107. Dimension Therapeutics Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 108. Dimension Therapeutics Hemophilia Drugs Product
Table 109. Dimension Therapeutics Recent Developments/Updates
Table 110. F. Hoffmann-La Roche Corporation Information
Table 111. F. Hoffmann-La Roche Description and Business Overview
Table 112. F. Hoffmann-La Roche Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. F. Hoffmann-La Roche Hemophilia Drugs Product
Table 114. F. Hoffmann-La Roche Recent Developments/Updates
Table 115. Grifols Corporation Information
Table 116. Grifols Description and Business Overview
Table 117. Grifols Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. Grifols Hemophilia Drugs Product
Table 119. Grifols Recent Developments/Updates
Table 120. Octapharma Corporation Information
Table 121. Octapharma Description and Business Overview
Table 122. Octapharma Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 123. Octapharma Hemophilia Drugs Product
Table 124. Octapharma Recent Developments/Updates
Table 125. Sangamo Biosciences Corporation Information
Table 126. Sangamo Biosciences Description and Business Overview
Table 127. Sangamo Biosciences Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 128. Sangamo Biosciences Hemophilia Drugs Product
Table 129. Sangamo Biosciences Recent Developments/Updates
Table 130. Spark Therapeutics Corporation Information
Table 131. Spark Therapeutics Description and Business Overview
Table 132. Spark Therapeutics Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 133. Spark Therapeutics Hemophilia Drugs Product
Table 134. Spark Therapeutics Recent Developments/Updates
Table 135. Swedish Orphan Biovitrum Corporation Information
Table 136. Swedish Orphan Biovitrum Description and Business Overview
Table 137. Swedish Orphan Biovitrum Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 138. Swedish Orphan Biovitrum Hemophilia Drugs Product
Table 139. Swedish Orphan Biovitrum Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Hemophilia Drugs Distributors List
Table 143. Hemophilia Drugs Customers List
Table 144. Hemophilia Drugs Market Trends
Table 145. Hemophilia Drugs Market Drivers
Table 146. Hemophilia Drugs Market Challenges
Table 147. Hemophilia Drugs Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Hemophilia Drugs
Figure 2. Global Hemophilia Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Hemophilia Drugs Market Share by Type in 2022 & 2029
Figure 4. Hemophilia A Product Picture
Figure 5. Inhibitors Product Picture
Figure 6. Hemophilia B Product Picture
Figure 7. Von Willebrand Disease Product Picture
Figure 8. Global Hemophilia Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Hemophilia Drugs Market Share by Application in 2022 & 2029
Figure 10. Recombinant Therapies
Figure 11. Plasma-Derived Therapies
Figure 12. Global Hemophilia Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Hemophilia Drugs Market Size (2018-2029) & (US$ Million)
Figure 14. Global Hemophilia Drugs Sales (2018-2029) & (K Units)
Figure 15. Global Hemophilia Drugs Average Price (USD/Unit) & (2018-2029)
Figure 16. Hemophilia Drugs Report Years Considered
Figure 17. Hemophilia Drugs Sales Share by Manufacturers in 2022
Figure 18. Global Hemophilia Drugs Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Hemophilia Drugs Players: Market Share by Revenue in 2022
Figure 20. Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Hemophilia Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Hemophilia Drugs Sales Market Share by Country (2018-2029)
Figure 23. North America Hemophilia Drugs Revenue Market Share by Country (2018-2029)
Figure 24. U.S. Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Hemophilia Drugs Sales Market Share by Country (2018-2029)
Figure 27. Europe Hemophilia Drugs Revenue Market Share by Country (2018-2029)
Figure 28. Germany Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Hemophilia Drugs Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Hemophilia Drugs Revenue Market Share by Region (2018-2029)
Figure 35. China Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Taiwan Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Philippines Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America Hemophilia Drugs Sales Market Share by Country (2018-2029)
Figure 46. Latin America Hemophilia Drugs Revenue Market Share by Country (2018-2029)
Figure 47. Mexico Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Hemophilia Drugs Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Hemophilia Drugs Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. U.A.E Hemophilia Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Hemophilia Drugs by Type (2018-2029)
Figure 56. Global Revenue Market Share of Hemophilia Drugs by Type (2018-2029)
Figure 57. Global Hemophilia Drugs Price (USD/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of Hemophilia Drugs by Application (2018-2029)
Figure 59. Global Revenue Market Share of Hemophilia Drugs by Application (2018-2029)
Figure 60. Global Hemophilia Drugs Price (USD/Unit) by Application (2018-2029)
Figure 61. Hemophilia Drugs Value Chain
Figure 62. Hemophilia Drugs Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Hemophilia A Drug Market Insights: Impact of COVID-19 and Future Expectations to 2028

Published: 23-May-2023        Price: US 3260 Onwards        Pages: 118

Factor VIII procoagulant component (VIII: C) deficiency, also known as AGH deficiency, is a sexually associated recessive genetic disease, transmitted by women, and male. The Hemophilia A Drug market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Hemophilia A Drug industry, and breaks down according to the type, applicatio......

Global Deep Vein Thrombosis (DVT) Drug Market Insights: Impact of COVID-19 and Future Expectations to 2028

Published: 23-May-2023        Price: US 3260 Onwards        Pages: 97

The Deep Vein Thrombosis (DVT) Drug market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Deep Vein Thrombosis (DVT) Drug industry, and breaks down according to the type, application, and consumption area of Deep Vein Thrombosis (DVT) Drug. The report also introduces players in the industry from the perspective of the industry ch......

Global Intravenous Immunoglobulin (IVIg) Market Size, Share and Industry Analysis by Regions, Countries, Types, and Applications, Forecast to 2028

Published: 19-May-2023        Price: US 3480 Onwards        Pages: 114

The global Intravenous Immunoglobulin (IVIg) market size was valued at USD 13315.76 Million in 2022 and will reach USD 24771.66 Million in 2028, with a CAGR of 10.9% during 2022-2028. Intravenous Immunoglobulin (IVIG) is a solution of highly purified Immunoglobulin G, derived from large pools of human plasma that contain antibodies against a broad spectrum of bacterial and viral agents. Influence of COVID-19 Outbreak on Intravenous Immunoglobulin (IVIg) Industry Deve......

Global Intravenous Immunoglobulin Market Insights: Impact of COVID-19 and Future Expectations to 2028

Published: 18-May-2023        Price: US 3260 Onwards        Pages: 106

Intravenous immune globulin (IVIG) is a product prepared from human plasma used to treat a variety of immunodeficiency and autoimmune conditions. The Intravenous Immunoglobulin market revenue was 12435.3 Million USD in 2022, and will reach 19485.47 Million USD in 2028, with a CAGR of 7.77% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Intravenous Immunoglobulin industry, and breaks down according to the type, appl......

2023-2031 Report on Global Anticoagulants Market by Player, Region, Type, Application and Sales Channel

Published: 24-Apr-2023        Price: US 2500 Onwards        Pages: 103

This report studies the Anticoagulants market, covering market size for segment by type (Platelet aggregation inhibitors (PAI), Low-molecular-weight Heparin (LMWH), etc.), by application (VTE, ACS/MI, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Sanofi, Bayer, Boehringer Ingelheim, Johnson & Johnson, Genentech (Roche), etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed histo......

2023-2031 Report on Global Low Molecular Weight Heparin Market by Player, Region, Type, Application and Sales Channel

Published: 24-Apr-2023        Price: US 2500 Onwards        Pages: 92

This report studies the Low Molecular Weight Heparin market, covering market size for segment by type (Enoxaparin, Dalteparin, etc.), by application (Treatment of Venous Thromboembolism, Complications of Pregnancy, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Aspen, Sanofi-aventis, Pfizer, Opocrin, CSBIO, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis......

Global Heparin Market Insights: Impact of COVID-19 and Future Expectations to 2028

Published: 13-Apr-2023        Price: US 3260 Onwards        Pages: 121

The Heparin market revenue was 7285.21 Million USD in 2022, and will reach 8765.54 Million USD in 2028, with a CAGR of 3.13% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Heparin industry, and breaks down according to the type, application, and consumption area of Heparin. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.......

Global Fibrinogen Concentrates Market Insights: Impact of COVID-19 and Future Expectations to 2028

Published: 06-Apr-2023        Price: US 3260 Onwards        Pages: 107

Fibrinogen, also known as coagulation factor I, is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen deficiency is a rare bleeding disorder characterized by mild to severe form of bleeding. The three types for fibrinogen deficiencies are: afibrinogenemia, hypofibrogenemia, and dysfibrinogenemia. In severely bleeding patients, fibrinogen concentrate significantly improves whole blood clot firmness and reduces the postoperative transfusion requirements. Currently......

2023-2031 Report on Global Intravenous Immunoglobulin Market by Player, Region, Type, Application and Sales Channel

Published: 04-Apr-2023        Price: US 2500 Onwards        Pages: 100

This report studies the Intravenous Immunoglobulin market, covering market size for segment by type (IVIg Liquid, IVIg Powder, etc.), by application (Immunodeficiency, Autoimmune Disease, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Baxter, Grifols, CSL, Octapharma, Biotest, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Intraveno......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs